Edward Nash Analyst PerformanceManaging Director at Canaccord Genuity GroupEdward Nash is a stock analyst at Canaccord Genuity Group in the healthcare sector, covering 26 publicly traded companies. Over the past year, Edward Nash has issued 44 stock ratings, including strong buy, buy, and hold recommendations. While full access to Edward Nash's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Edward Nash's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings74 Last 11 YearsBuy Recommendations86.49% 64 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution74RatingsDistribution of strong buy, buy, hold, and sell ratings by Edward Nash.RatingPercentageCount Strong Buy1.4%1 ratings Buy85.1%63 ratings Hold13.5%10 ratings Sell0.0%0 ratingsOut of 74 total stock ratings issued by Edward Nash at Canaccord Genuity Group, the majority (85.1%) have been Buy recommendations, followed by 13.5% Hold and 1.4% Strong Buy.Best & Worst CallsBest Call0000.0%MDGLMay 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%OBSVApr 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.2% of companies on NASDAQ25 companiesTSE3.8% of companies on TSE1 companyEdward Nash, an analyst at Canaccord Genuity Group, currently covers 26 companies listed on NASDAQ and TSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare26 companies100.0%Edward Nash of Canaccord Genuity Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY18 companies69.2%PHARMACEUTICALS8 companies30.8% Edward Nash's Ratings History at Canaccord Genuity Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsVKTXViking Therapeutics7/30/2026Boost Price Target$32.47$114.00Buy$0.0000.00% ROITVTXTravere Therapeutics7/30/2026Boost Price Target$56.26$62.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals7/29/2026Boost Price Target$538.19$587.00Buy$0.0000.00% ROICORTCorcept Therapeutics7/29/2026Boost Price Target$94.36$150.00Buy$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International7/29/2026Boost Price Target$80.57$98.00Buy$0.0000.00% ROICLDXCelldex Therapeutics7/22/2026Lower Price Target$35.66$60.00Buy$0.0000.00% ROINKTRNektar Therapeutics7/22/2026Initiated Coverage$68.67$153.00Buy$0.0000.00% ROIKYMRKymera Therapeutics6/26/2026Boost Price Target$118.34$129.00Buy$0.0000.00% ROIAPGEApogee Therapeutics6/22/2026Downgrade$132.65$135.11Hold$0.0000.00% ROIVERUVeru6/4/2026Reiterated Rating$5.57$25.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CORTCorcept Therapeutics5/28/2026Boost Price Target$69.46$135.00Buy$0.0000.00% ROICNTBConnect Biopharma5/26/2026Initiated Coverage$2.35$6.00Buy$0.0000.00% ROICNTBConnect Biopharma5/26/2026Initiated Coverage$2.40$6.00Buy$0.0000.00% ROIRANIRani Therapeutics5/20/2026Reiterated Rating$1.04$5.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals5/7/2026Lower Price Target$539.73$578.00Buy$0.0000.00% ROIKYMRKymera Therapeutics5/6/2026Initiated Coverage$82.71$106.00Buy$0.0000.00% ROISGMTSagimet Biosciences5/4/2026Boost Price Target$7.74$49.00Buy$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International4/29/2026Boost Price Target$52.54$64.00Buy$0.0000.00% ROIGPCRStructure Therapeutics4/27/2026Initiated Coverage$45.49$101.00Buy$0.0000.00% ROIGPCRStructure Therapeutics4/27/2026Upgrade$43.56$101.00Strong-Buy$0.0000.00% ROITVTXTravere Therapeutics4/14/2026Boost Price Target$40.97$56.00Buy$0.0000.00% ROICRDLCardiol Therapeutics4/6/2026Reiterated Rating$1.37$8.00Buy$0.0000.00% ROIRANIRani Therapeutics4/1/2026Lower Price Target$0.81$5.00Buy$0.0000.00% ROICORTCorcept Therapeutics3/26/2026Boost Price Target$38.74$110.00Buy$0.0000.00% ROIAPGEApogee Therapeutics3/24/2026Boost Price Target$73.74$130.00Buy$0.0000.00% ROIPLRXPliant Therapeutics3/13/2026Lower Price Target$1.36$3.00Hold$0.0000.00% ROIKNSAKiniksa Pharmaceuticals International2/19/2026Initiated Coverage$45.39$62.00Buy$0.0000.00% ROICORTCorcept Therapeutics1/23/2026Boost Price Target$41.30$100.00Buy$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Downgrade$13.73$14.00Hold$0.0000.00% ROICORTCorcept Therapeutics1/2/2026Lower Price Target$34.80$99.00Buy$0.0000.00% ROIVERUVeru12/18/2025Initiated Coverage$2.23$25.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/13/2025Boost Price Target$514.84$587.00Buy$0.0000.00% ROIVKTXViking Therapeutics11/12/2025Boost Price Target$40.60$107.00Buy$0.0000.00% ROIVTYXVentyx Biosciences11/7/2025Boost Price Target$8.77$16.00Buy$0.0000.00% ROIVKTXViking Therapeutics10/29/2025Initiated Coverage$34.93$106.00Buy$0.0000.00% ROIAKROAkero Therapeutics10/9/2025Downgrade$54.24$54.00Hold$0.0000.00% ROISGMTSagimet Biosciences10/2/2025Reiterated Rating$6.98$28.00Buy$0.0000.00% ROIIVAInventiva9/30/2025Reiterated Rating$5.71$20.00Buy$0.0000.00% ROICORTCorcept Therapeutics9/25/2025Reiterated Rating$83.84$140.00Buy$0.0000.00% ROICLDXCelldex Therapeutics9/17/2025Reiterated Rating$24.64$62.00Buy$0.0000.00% ROITrump Takes Emergency Action - Plus Elon Musk's New Venture (Ad)Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.See which companies control the supply chain behind this emerging techMDGLMadrigal Pharmaceuticals9/12/2025Boost Price Target$439.45$526.00Buy$0.0000.00% ROICORTCorcept Therapeutics9/10/2025Boost Price Target$73.48$140.00Buy$0.0000.00% ROICLDXCelldex Therapeutics8/20/2025Lower Price Target$22.11$62.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals8/6/2025Boost Price Target$335.67$428.00Buy$0.0000.00% ROICORTCorcept Therapeutics8/1/2025Lower Price Target$68.52$137.00Buy$000.0000.00% ROISGMTSagimet Biosciences7/24/2025Initiated Coverage$9.59$28.00Buy$0.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share7/9/2025Downgrade$104.77$107.00Hold$0.0000.00% ROIMDGLMadrigal Pharmaceuticals5/2/2025Boost Price Target$327.81$420.00Buy$000.0000.00% ROICLDXCelldex Therapeutics4/28/2025Initiated Coverage$19.57$64.00Buy$00.0000.00% ROITVTXTravere Therapeutics4/10/2025Boost Price Target$13.42$47.00Buy$00.0000.00% ROICORTCorcept Therapeutics4/1/2025Boost Price Target$102.62$142.00Buy$00.0000.00% ROIRANIRani Therapeutics2/26/2025Reiterated Rating$1.55$9.00Buy$0.0000.00% ROIVRNAVerona Pharma PLC American Depositary Share2/12/2025Boost Price Target$59.33$72.00Buy$0.0000.00% ROITVTXTravere Therapeutics2/12/2025Boost Price Target$23.75$45.00Buy$00.0000.00% ROIPLRXPliant Therapeutics2/10/2025Reiterated Rating$7.79$4.00Hold$0.0000.00% ROICORTCorcept Therapeutics1/30/2025Boost Price Target$69.89$130.00Buy$00.0000.00% ROIAKROAkero Therapeutics1/28/2025Boost Price Target$51.37$73.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
